Pub. Date : 2018
PMID : 29773061
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Targeting mutant IDH by development of small molecule inhibitors is a rapidly emerging therapeutic approach as evidenced by the recent approval of the first selective mutant IDH2 inhibitor AG-221 (enasidenib) for the treatment of IDH2-mutated AML. | enasidenib | isocitrate dehydrogenase (NADP(+)) 1 | Homo sapiens |
| 2 | Targeting mutant IDH by development of small molecule inhibitors is a rapidly emerging therapeutic approach as evidenced by the recent approval of the first selective mutant IDH2 inhibitor AG-221 (enasidenib) for the treatment of IDH2-mutated AML. | enasidenib | isocitrate dehydrogenase (NADP(+)) 1 | Homo sapiens |